Istari Oncology, Inc. With a passionate and experienced leadership team, we are focused on devising effective clinical trial strategies and driving execution. Our goal is to collaborate with leading cancer centers and oncology biotech firms to explore partnership opportunities.

Our key asset is lerapolturev, an investigational immunotherapy based on the Sabin oral poliovirus vaccine. We have genetically engineered it to eliminate neurotoxicity and leverage multiple unique mechanisms of action to activate a systemic antitumor response in the fight against cancer. At Istari, our mission is to pioneer a new field of immunotherapies to provide hope to patients battling cancer.

Our commitment to improving lives through a data-driven approach and a desire for positive patient outcomes drives us. Our culture promotes teamwork, scientific debate, and compassion. We value collaboration and are willing to take on any task, no matter how small.

And while we take our work seriously, we make sure to celebrate our accomplishments with a healthy dose of fun. Join us in our fight against cancer